Group 1 - The company reported a revenue of 2.473 billion yuan for the fiscal year 2025, representing a year-on-year decrease of 8.33% [1] - The net profit attributable to the parent company was 251 million yuan, down 40.30% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 160 million yuan, a decrease of 57.67% year-on-year [1] Group 2 - The company's subsidiary, Shenzhen New Industry Ophthalmic New Technology Co., faced significant operational pressure due to the second phase of the national volume-based procurement for artificial lenses and intensified industry competition [2] - The total number of cataract surgeries in China in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - The increase in domestic competitors, particularly those offering significant cost advantages, has negatively impacted the sales price and volume of the imported Lenstec brand products [2] - The company anticipates a decrease in sales profit for Shenzhen New Industry in 2025 and has prudently recognized an impairment provision of approximately 140 million yuan for goodwill [2]

Core Viewpoint - The company, Haohai Biological Technology, reported a significant decline in its financial performance for the fiscal year 2025, with total revenue and net profit both decreasing substantially compared to the previous year [1][2]. Financial Performance - Total revenue for 2025 was approximately 2.473 billion yuan, representing a year-on-year decrease of 8.33% [1]. - Net profit attributable to the parent company was around 251 million yuan, down 40.3% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was about 160 million yuan, reflecting a 57.67% decrease compared to the previous year [1]. - Basic earnings per share were reported at 1.08 yuan [1]. Market Conditions - The company faced significant operational pressure in its subsidiary, Shenzhen New Industry, due to the second phase of the national volume-based procurement for artificial lenses, leading to increased competition and a decline in market demand [2]. - The total number of cataract surgeries in China in 2025 is expected to decrease compared to 2024, contributing to a downturn in overall market demand [2]. - The sales price and volume of Lenstec brand products continued to decline throughout 2025, impacting the expected operating profit of Shenzhen New Industry [2]. Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for the goodwill associated with Shenzhen New Industry, in light of the anticipated price reductions in the upcoming round of national volume-based procurement [2]. - The impairment amount is subject to final assessment and audit by qualified evaluation and auditing institutions [2]. - Additionally, the company's U.S. subsidiary, Aaren Scientific Inc., has also indicated signs of impairment for its intangible assets, leading to a preliminary impairment provision of about 24.98 million yuan [3].